MODD

Business Context and Reporting Period

Company: Modular Medical, Inc. (MODD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 31, 2026
Business Overview: Modular Medical is a commercial-stage medical device company developing innovative insulin pumps. The company recently launched its "Pivot" patch pump, a tubeless, reusable device designed to simplify insulin delivery for Type 1 and Type 2 diabetes patients. The company targets "Almost Pumpers"—patients who desire pump therapy but are deterred by the complexity and cost of existing devices.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no revenue as it is in the early commercialization phase.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by approximately $9.4 million (50%) year-over-year, driven by higher Research and Development (R&D) and General and Administrative (G&A) expenses.
• R&D Expenses: Increased 36% to $20.0 million, primarily due to higher personnel costs, consulting fees, and depreciation related to manufacturing equipment for the Pivot product.
• G&A Expenses: Increased 74% to $7.6 million, attributed to increased headcount, consulting, and sales/marketing activities in preparation for commercial launch.
• Cash Position: Cash and cash equivalents decreased by $6.2 million to $6.9 million, despite significant financing inflows, due to high operating burn rates.
• Stock Split: The company effected a 1-for-30 reverse stock split effective March 31, 2026, to comply with Nasdaq listing requirements.

Guidance, Outlook, and Risks

Outlook and Management Commentary

• Commercial Launch: The company announced commercial availability and initial shipments of the Pivot insulin delivery system in June 2026. Expansion across metropolitan markets is planned for late 2026.
• Regulatory Status: Received FDA clearance for the Pivot pump in April 2026. The company intends to seek CE mark clearance for European markets by Q2 2027.
• Capital Needs: Management states there is "substantial doubt" about the company's ability to continue as a going concern for the next 12 months without additional financing. The company plans to raise capital through equity or debt offerings.
• Recent Financing: Closed a public offering in March 2026 raising approximately $12.0 million and a registered direct offering in April 2026 raising approximately $3.4 million.

Risks and Contingencies

• Going Concern: The independent auditor has expressed substantial doubt regarding the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• Reimbursement Uncertainty: The Pivot pump is not yet approved for insurance coverage or reimbursement. Commercial success depends heavily on securing third-party payor coverage.
• Manufacturing and Supply Chain: The company relies on third-party manufacturers (Phillips Medisize) and suppliers. Supply chain disruptions or quality issues could delay commercialization.
• Competition: The market is dominated by larger competitors (Insulet, Tandem, Medtronic) with established products and significant financial resources.

Investor Verification Checklist

• Reimbursement Strategy: Verify the specific timeline and progress regarding insurance coverage and reimbursement approvals for the Pivot pump, as this is critical for revenue generation.
• Cash Runway: Confirm the sufficiency of the $6.9 million cash balance plus recent financing proceeds to fund operations through the next 12 months given the high burn rate.
• Commercial Traction: Monitor initial shipment volumes and customer adoption rates following the June 2026 launch to assess market acceptance.
• Dilution Risk: Review terms of future capital raises, as the company explicitly states it will need substantial additional funding, likely resulting in significant shareholder dilution.
• Manufacturing Scale-up: Assess the company's ability to scale production with its contract manufacturer to meet potential demand without quality control failures.